NeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations
Key Highlights
- ➤FDA granted Type B meeting to discuss NEO100 accelerated-approval pathway in early January 2027
- ➤NEO100 Phase 2a six-month progression-free survival reached 48.9% versus 20% benchmark
- ➤BTIG reiterated Buy rating and $15 price target for NeOnc
- ➤CEO Amir F. Heshmatpour bought approximately $333,100 of NTHI shares
- ➤NEO100 and NEO212 clinical updates scheduled for November 13 at SNO meeting
Expert Statements
Amir F. Heshmatpour, CEO of NeOnc Technologies Holdings
“The company intends to ask the FDA whether its existing clinical and nonclinical package could support a 505(b)(2) New Drug Application seeking accelerated approval under Section 506(c) of the Federal Food, Drug, and Cosmetic Act.”
Jonathan Aschoff, Analyst at Roth MKM
“Buy rating and $20 price target”
Jason McCarthy, Analyst at Maxim Group
“Buy rating and $20 target”
Matthew Venezia, Analyst at Alliance Global Partners
“Buy rating and $13 target”
DENVER, Nov. 12, 2026 (GLOBE NEWSWIRE) -- (247MarketNews) — NeOnc Technologies Holdings (NASDAQ: NTHI) is heading into a potentially important period for its clinical programs, with additional insider purchases coinciding with a newly announced FDA meeting that could help determine the development pathway for its investigational brain cancer therapy, NEO100.
Two Form 4 filings dated November 12 add important detail to the company's recent insider-buying activity. CEO Amir F. Heshmatpour reported purchasing 80,000 shares across November 19-11, including 50,000 shares at a weighted average price of $4.192, another 10,000 shares at $4.49, 10,000 shares at $4.00, and 10,000 shares at $3.86. The reported transactions represent approximately $333,100 in additional open-market purchases. His directly held common stock position increased to 3,333,000 shares following the transactions.
Get started
Create a free account to read the full story.